Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Given the success of venetoclax in the clinical setting thus far, it is likely that BCL-2 inhibition will take on an increasingly important role in the treatment of CLL going forward.
|
31764121 |
2020 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies.
|
31821686 |
2020 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Knowledge of the genetic landscape of CLL has allowed the identification of the main molecular features associated with chemo-refractoriness, as well as resistance to BCR inhibitors and BCL2 inhibitors.
|
31774349 |
2020 |
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The characteristic high-level expression of BCL2 in CLL that can enhance leukemia-cell survival has now become an Achilles heel targeted by clinically effective drugs such as venetoclax.
|
31764118 |
2020 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.
|
30601084 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL).
|
30768675 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The prevalence, clinicopathologic correlates, and outcomes of previously untreated chronic lymphocytic leukemia (CLL) patients with IGH-BCL2 and IGH-BCL3 translocations are not well known.
|
30575108 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptor (IP<sub>3</sub>R)-mediated Ca<sup>2+</sup>-signaling.
|
29899382 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ovarian gene expressions of angiotensin converting enzyme 2 (ACE2), Mas receptor, tumor necrosis factor alpha (TNF-α) and B-cell leukemia/lymphoma-2 (BCL-2) were estimated.
|
31494171 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, GFX could activate the caspase-8, caspase-9, and caspase-3, induce MTP disruption, downregulate B-cell leukemia-2 (Bcl-2) and B-cell leukemia-XL (Bcl-XL), and upregulate Bcl-2 assaciated X protein (Bax), Bcl-2-associated death promoter (Bad), Bcl-2 interacting domain (Bid) and cytoplasmic cytochrome C in SFs, suggesting that caspase-dependent extrinsic and intrinsic pathways were related to GFX-contributed apoptosis of SFs.
|
31637186 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Meta-analysis of seven randomized trials comprising 2409 patients with R/R CLL revealed that improvement over traditional treatments observed with BCR or BCL2 pathway inhibitors is common to all patients, including those patients with unfavorable and favorable prognostic parameters.
|
30516079 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, the apoptosis rate and the levels of apoptosis marker proteins including B cell leukemia/lymphoma 2 (Bcl2) and Bcl2-associated X protein (Bax) were also measured and the results showed that Cd-induced apoptosis was markedly inhibited by Tre treatment.
|
31650140 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia.
|
30975914 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SIGNIFICANCE: Why CLL recurs in patients who achieve remission with the BCL2 inhibitor venetoclax has been unknown.
|
30514704 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.
|
31166681 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) has dramatically improved thanks to the development of mechanism-driven agents including drugs that inhibit kinases in the BCR pathway or BCL2.
|
30858962 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Venetoclax is a highly specific novel agent inhibiting the bcl-2 anti-apoptotic pathway and has potent activity in CLL.
|
31205643 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Venetoclax, an antagonist of BCL-2 protein plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL).
|
30969139 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Small molecule inhibitors of the cellular pro-survival BCL-2 family proteins, termed 'BH3-mimetics', have entered clinical trials for blood cancers with the BCL-2 inhibitor venetoclax already approved for treatment of therapy refractory chronic lymphocytic leukaemia and acute myeloid leukaemia in the elderly.
|
31645677 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The BCL-2 specific inhibitor, venetoclax/ABT-199 has exhibited remarkable clinical activity in nearly all cases of chronic lymphocytic leukemia.
|
31601689 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Tested parameters included, estimation of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and glucose levels, testicular samples for histopathology and estimation of malondialdehyde (MDA), total antioxidant capacity (TAC), and B-cell leukemia/lymphoma-2 (BCL-2) levels as well as sperm count and motility.
|
30317639 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
New classes of drugs, such as kinase inhibitors and BCL-2 protein antagonists, have been approved for treatment of CLL patients.
|
31239767 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The expression of proteins related to apoptosis, cysteinyl aspartate-specific proteinase 12 (caspase-12) and B-cell leukemia 2 (Bcl-2), was measured by western blot.
|
30704457 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor approved for use as monotherapy or with rituximab in patients with chronic lymphocytic leukemia (CLL).
|
31209657 |
2019 |
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> ESCs: endometrial stromal cells; 17β-E2: 17β-Estradiol; EMT: epithelial-mesenchymal transition; CASP3: caspase 3; BCL2: B cell leukemia/lymphoma 2; VEGFA: vascular endothelial growth factor A; lncRNA: long non-coding RNA; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; RT-qPCR: reverse transcription-quantitative polymerase chain reaction.
|
30608887 |
2019 |